<th id="8ilbc"><pre id="8ilbc"></pre></th>
<button id="8ilbc"><acronym id="8ilbc"></acronym></button>

<span id="8ilbc"><pre id="8ilbc"><sup id="8ilbc"></sup></pre></span><dd id="8ilbc"><noscript id="8ilbc"></noscript></dd>
<th id="8ilbc"><track id="8ilbc"></track></th>

  • <button id="8ilbc"><object id="8ilbc"></object></button>

    <em id="8ilbc"></em>
  • <em id="8ilbc"><ruby id="8ilbc"><input id="8ilbc"></input></ruby></em>

        <em id="8ilbc"><ruby id="8ilbc"><input id="8ilbc"></input></ruby></em>

        (Richard Miller MD)
        Co-founder, Chairman and CEO

        Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School, summa cum laude. He is a board-certified oncologist and is currently Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center.

        (Ted Wang Ph.D.)
        Co-founder, General Manager and Director

        Mr. Wang is the founder of Puissance Capital and brings with him 24 years of global equities trading and investing experience. Mr. Wang was a Partner of Goldman, Sachs & Co and during his 18-year tenure at the firm he held many leadership positions, mostly recently as Co-Head of US Equities Trading and Global Co-Head of One Delta Trading and a member of the Goldman Sachs Risk Committee. At his retirement, he was the most senior Chinese partner at the firm and was deeply involved in the firm’s strategy in China. He holds a PhD in Physics from the University of Minnesota, an MBA from the University of Texas, Austin, and a BS from Fudan University, China. He is co-chair of the board of trustees of the Museum of Chinese in America, a trustee of the China Institute, the Dunhuang Foundation, the Spence School, and a member of Committee of 100.

        (Leiv Lea)

        Mr. Lea served as the Chief Financial Officer of Pharmacyclics from 1998 to 2008. He received a B.S. in agricultural economics from the University of California, Davis, and an M.B.A. from the Anderson School at the University of California, Los Angeles.

        (Peter Thompson MD)

        Peter Thompson, M.D is a Partner on the private equity team, with over 25 years of industry experience. He held executive positions at Becton-Dickinson and Chiron, co-founded and was CEO of Trubion Pharmaceuticals, co-founded Corvus Pharmaceuticals, Cleave Biosciences, Silverback Therapeutics and serves as a Director on several company boards. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents and a board-certified internist and oncologist. He was on staff at the National Cancer Institute following his internal medicine training at Yale University.

        91视频久久久_亚洲欧美18岁网站_久久97超碰国产精品_亚洲 欧洲 日韩 综合在线